INT263128

Context Info Confidence 0.22 First Reported 2008 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 3 Total Number 3 Disease Relevance 1.33 Pain Relevance 0.18

cytosol (PDE4A) signal transduction (PDE4A) plasma membrane (PDE4A) nucleus (PDE4A) cytoplasm (PDE4A)

Anatomy Link Frequency B-cell 2 PDE4A (Homo sapiens)

Pain Link Frequency Relevance Heat Inflammation 76 92.64 Inflammatory mediators 8 5.00 adenocard 4 5.00 imagery 3 5.00 antagonist 2 5.00 cytokine 2 5.00 fibrosis 2 5.00 cINOD 2 5.00 Neurotransmitter 2 5.00 Inflammatory response 2 5.00

Disease Link Frequency Relevance Heat Shock 1 98.32 Cancer 33 95.80 Hodgkin's Disease 8 94.96 INFLAMMATION 88 92.64 Acromegaly 8 85.56 Reprotox - General 2 4 70.64 Obesity 4 62.44 Lymphatic System Cancer 5 57.04 Adrenal Cancer 10 33.92 Thyroid Neoplasm 2 14.64

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Siguazodan, a PDE3 inhibitor, potentiated relaxation induced by rolipram suggesting an interaction between PDE3 inhibition and PDE4 inhibition (Torphy et al 1993).

Negative_regulation (inhibition) of PDE4 Binding (interaction) of

1) Confidence 0.22 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.31 Pain Relevance 0.09

Siguazodan, a PDE3 inhibitor, potentiated relaxation induced by rolipram suggesting an interaction between PDE3 inhibition and PDE4 inhibition (Torphy et al 1993).

Negative_regulation (inhibition) of PDE4 Binding (interaction) of

2) Confidence 0.22 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.31 Pain Relevance 0.09

The R81X is a known functional mutation that codes for a truncated protein lacking the tetratricopeptide repeat (TPR) carboxy terminal domains, which are essential for AIP to bind to the aryl hydrocarbon receptor (AHR) and heat shock 90 (HSP90).12,27 Previous in vitro studies of the R81X mutation have shown that it blocks the interaction of wild type AIP and phosphodiesterase type 4A (PDE4A), potentially disrupting the cAMP cascade.28 AIP somatic status in the somatotropinoma, adrenocortical tumor and B-cell non-Hodgkin lymphoma

Negative_regulation (blocks) of PDE4A Binding (interaction) of in B-cell associated with cancer, shock and hodgkin's disease

3) Confidence 0.06 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2862671 Disease Relevance 0.71 Pain Relevance 0

General Comments

This test has worked.